MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12935-023-03071-w

Медицинская библиотека · Cancer cell international · 2023

RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma.

Tsai Yu-Fen, Chan Leong-Perng, Chen Yuk-Kwan, Su Chang-Wei, Hsu Ching-Wei, Wang Yen-Yun, Yuan Shyng-Shiou F

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

RAD51 overexpression has been reported to serve as a marker of poor prognosis in several cancer types. This study aimed to survey the role of RAD51 in oral squamous cell carcinoma and whether RAD51 could be a potential therapeutic target.

MATERIALS AND

METHODS

RAD51 protein expression, assessed by immunohistochemical staining, was used to examine associations with survival and clinicopathological profiles of patients with oral squamous cell carcinoma. Lentiviral infection was used to knock down or overexpress RAD51. The influence of RAD51 on the biological profile of oral cancer cells was evaluated. Cell viability and apoptosis after treatment with chemotherapeutic agents and irradiation were analyzed. Co-treatment with chemotherapeutic agents and B02, a RAD51 inhibitor, was used to examine additional cytotoxic effects.

RESULTS

Oral squamous cell carcinoma patients with higher RAD51 expression exhibited worse survival, especially those treated with adjuvant chemotherapy and radiotherapy. RAD51 overexpression promotes resistance to chemotherapy and radiotherapy in oral cancer cells in vitro. Higher tumorsphere formation ability was observed in RAD51 overexpressing oral cancer cells. However, the expression of oral cancer stem cell markers did not change in immunoblotting analysis. Co-treatment with RAD51 inhibitor B02 and cisplatin, compared with cisplatin alone, significantly enhanced cytotoxicity in oral cancer cells.

CONCLUSION

RAD51 is a poor prognostic marker for oral squamous cell carcinoma. High RAD51 protein expression associates with resistance to chemotherapy and radiotherapy. Addition of B02 significantly increased the cytotoxicity of cisplatin. These findings suggest that RAD51 protein may function as a treatment target for oral cancer.

TRIAL REGISTRATION: Number: KMUHIRB-E(I)-20190009 Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, approved on 20190130, Retrospective registration.

Для цитирования: Tsai Yu-Fen, Chan Leong-Perng, Chen Yuk-Kwan, Su Chang-Wei, Hsu Ching-Wei, Wang Yen-Yun, Yuan Shyng-Shiou F. RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma.. Cancer cell international. 2023. DOI: 10.1186/s12935-023-03071-w.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.